The ASH
people sent news and updates from the haematology/oncology community with some
highlights of this week’s developments:
|
||
|
FDA Announces Plans to Advance Digital Health Care The U.S. Food and Drug Administration has announced a pilot program allowing medical software companies to “pre-certify” for marketing digital devices and products. |
||
|
Eculizumab Associated With Increased Risk of Meningococcal Disease A report from the Centers for Disease Control and Prevention, noted that eculizumab – an FDA-approved drug for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome – is associated with a 1,000- to 2,000-fold risk of meningococcal disease. |
||
|
||
|
Carfilzomib Combination Has Manageable Toxicity in Patients With Newly Diagnosed MM CHAMPION-2 researchers found that carfilzomib plus cyclophosphamide and dexamethasone is a safe option for patients with newly diagnosed multiple myeloma; the combination was associated with a high response rate. |
No comments:
Post a Comment